About Diabetes Metabolic Restorative Therapy


Diabetes Metabolic Restorative Therapy (DMRT) is a protocol-based pulsatile insulin infusion therapy that mimics the coordinated pulsatile secretion of insulin in response to a carbohydrate challenge of the beta cells in the normal pancreas. PII is thought to trigger the liver to initiate glycogen storage and its enzymatic metabolic response to a carbohydrate challenge in non-diabetics.  It is not a cure for diabetes, but rather a means of arresting and often reversing the progression of complications of the disease. Various versions and protocols of the therapy have been tested and referenced in the literature dating back to the 1930s, but well-designed and unbiased clinical trials with control groups are indicated and in process.

A majority of patients experience positive outcomes previously thought impossible. They enjoy an overall improvement in the way they feel, have more energy, experience better sleep patterns, and have a more positive mental outlook creating a huge general boost in their quality of life. Treatments are reimbursed by most insurance and managed care plans.

Everything about the new Diabetic Treatment Center is different. In our clinical environment, we provide the DMRT PII treatment in a manner that allows patients to be comfortable, encouraging our patients to move around, watch TV, read, even socialize with other patients.

The Evolution of DMRT

The following studies represent the evolution of the scientific bases of pulsatile therapy:

1979 - Dr. Walter Paul Van Helder, PhD discovers the pulse activity of the liver as it relates to the pancreas.

1983 – Matthews – Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes 32(7): 617-621 

1986 – Komjati – Pulsatile insulin superior to continuous on hepatic glucose production. Endocrinology 118(1): 312-319 

1990 – Paolisso – Pulsatile insulin therapy delivery has greater metabolic effects than continuous hormone adinistration in man: Importance of pulse frequency. Diabetes 61: 2269-2279

2000 – Dailey – Effects of pulsatile insulin therapy on the progression of diabetic nephropathy. Metabolism 49(1): 1491-1495

2009 – Mirbolooki – Pulsatile intravenous insulin therapy: the best practice to reverse diabetic complications? Medical Hypotheses 73: 363-369

2010 – Weinrauch – Pulsatile intermittent insulin therapy for attenuation of retinopathy. Metabolism 59(10): 1429-1434

2012 – Matveyenko – Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes 61: 2269-2279   

2012 – Wahrens – Loss of pulsatile insulin secretion: A factor in the pathogenesis of Type 2 diabetes. Diabetes 61(9): 2228-9

2015 – Satin – Pulsatile insulin secretion, impaired glucose tolerance and type 2 Diabetes. Molecular Aspects of Medicine 42 (2015) 61-77

2017 – Elliott – Microburst insulin infusion: Result of observational studies – Carbohydrate metabolism, painful diabetic neuropathy and hospital/emergency department utilization. J. Diabetes Metabolic Disorder Control 4(4): 00118